BBIO

BridgeBio Pharma Inc. (BBIO) | Rumor.io

BridgeBio Pharma

BBIO

Attention (50-day avg)0%

Attention rank (50-day avg)#792

Bullish sentiment (50-day avg)66%

Price to earnings ratio-17.6

Market capitalization13B

Earnings per share-3.62

Dividend yield (TTM)—

Revenue (annual)502.1M

Net income (annual)-732.9M

Social

What share of all stock conversation is about BBIO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.02	0.01% +0.01	0% 0	0% 0

Sep 23

BridgeBio Pharma's acoramidis has demonstrated real-world benefit versus tafamidis in ATTR-CM, reducing the risk of clinical worsening.
A new study evaluating the effectiveness of acoramidis versus tafamidis is expected to be released at an upcoming 2026 medical meeting.
Acoramidis is taking a healthy share of new starts with Attruby, with observational data favoring it by 34% on clinical worsening versus tafamidis.

Generated by AI

Sentiment

Of the messages about BBIO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	32.45% -45.81	59.36% -15.73	80.71% -2.24
Bearish	—	67.55% +45.81	40.64% +15.73	19.29% +2.24

Bullish· Apr 28

BridgeBio Pharma's ($BBIO) settlement with Pfizer ($PFE) has removed a significant overhang, providing clarity on the company's patent protection and improving its growth outlook.
Analysts are reiterating their bullish ratings on $BBIO, with price targets ranging from $100 to $157, citing improved IP visibility and limited near-term generic pressure.
The settlement with $PFE has led to a significant price increase for $BBIO, with the stock rising by 18% and reaching a new high, making it a "screaming buy" according to some investors.

Bearish· Apr 28

The market is disappointed with the PFE settlement, which extends exclusivity to 2031, a shorter timeframe than expected, and is a negative for $BBIO.
The recent price action forms a double top at around $85, a bearish technical signal, and some investors are choosing to exit positions.
The PFE lawsuit settlement likely delays cheap generic heart drugs to 2031, which is a positive for $BBIO's new drug outlook and stock sentiment.

Generated by AI

Topics

Of the messages about BBIO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	34.38%	69.05%	83.57%
Technical Analysis	—	6.25%	5.36%	3.12%
Macro	—	0%	0.6%	1.32%
Analysts	—	0%	2.38%	6.95%
Earnings	—	0%	0%	1.77%
Controversies	—	59.38%	22.62%	3.27%

Analysts· Jul 14

Jefferies initiated coverage of BridgeBio Pharma with a Buy rating and $70 price target.
Piper Sandler raised their price target on BridgeBio to $68 from $63, maintaining an 'Overweight' rating.
Leerink raised BridgeBio's price target to $56 from $53, and Scotiabank has a 'Sector Outperform' rating with a $55 price target.

Announcements· Apr 28

Pfizer has reached three settlement agreements for Vyndamax, which extends the patent expiry to June 1, 2031, giving BridgeBio Pharma more time to grow its rival heart drug.
BridgeBio Pharma is a primary competitor to Pfizer in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) market, and the company is on track for its worst day in 2.5 months due to the Pfizer connection.
BridgeBio Pharma has launched a health education effort on often overlooked heart condition featuring Attruby, and Barclays sees a 103% price potential after FDA approval of the drug Attruby.

Technical Analysis· Jul 18

The author is watching $BBIO for a potential short scalp if it starts rolling over, and notes that it looks exhausted.
$BBIO is massively overbought, with an RSI in the 90s, and the author expects a fall to begin soon.
The author is looking to add a short position on $BBIO at 33.50, with a target of 36.10, and notes that the stock is struggling to stay above $35 resistance.

Generated by AI

Community

Of the messages about BBIO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	98.85%	92.96%	79.32%
Newcomers	—	1.15%	7.04%	20.68%

Regulars· Sep 23

Acoramidis, BridgeBio Pharma's (BBIO) treatment for ATTR-CM, has demonstrated real-world benefit versus Tafamidis, reducing the risk of clinical worsening.
An upcoming 2026 medical meeting is expected to release additional, independent real-world study evaluating the effectiveness of Acoramidis versus Tafamidis using electronic health records data.
BBIO's valuation is considered cheap, with a potential market share forecast increase of 30-40%, possibly driven by an upcoming analyst day.

Newcomers· Feb 28

The FDA has approved Ascendis Pharma's (ASND) weekly treatment for children with dwarfism, a rare form of short stature, sparking an anticipated options flow and an increase in volume.
The approval of Yuviwel, a terapy for pediatric genetic dwarfism, is a significant event that may lead to a sector rotation, with related stocks such as BridgeBio Pharma (BBIO) potentially experiencing increased activity.
The FDA's approval of Yuviwel is a catalyst play that may attract investors, with options flow and volume expected to increase, and related stocks such as BridgeBio Pharma (BBIO) worth monitoring for sector movement.

Generated by AI

Earlier this week, BridgeBio Pharma reported peer-reviewed real-world data in Cardiology and Therapy showing that its ATTR cardiomyopathy therapy acoramidis was associated with lower early clinical worsening risk versus tafamidis in newly treated patients over a mean follow-up of 4.6 months. The study offers the first head-to-head, real-world comparison between approved transthyretin stabilizers, potentially strengthening the clinical and commercial positioning of acoramidis as Attruby in...

2d agoYahoo Finance

BridgeBio Pharma (BBIO) Stock Looks Reasonable As Fresh Acoramidis Data Lands

BridgeBio Pharma has delivered a strong share price run in recent years, and that kind of move naturally raises the question of whether the current valuation still lines up with the sales that sit behind the story. With fresh real world data around its acoramidis therapy now in the mix, investors are asking how much revenue power is realistically being priced into the stock today. Over the past 3 years the stock has gained 148.7%, which puts real pressure on the question of how much sales...

2d agoYahoo Finance

BridgeBio Pharma Eyes Four Global Launches by 2027 as Attruby Nears Blockbuster Status

BridgeBio Pharma (NASDAQ:BBIO) expects 2027 to be a transformative year as it expands from one commercial product to four globally launched therapies, President and CFO Thomas Trimarchi said during a Bernstein discussion. Trimarchi said the company’s strategy centers on developing medicines for gen

4d agoYahoo Finance

BridgeBio at bernstein healthcare forum: four-product growth story builds

6d agoInvesting.com

BridgeBio says heart disease therapy Attruby beat Pfizer’s Vyndamax in real world study

6d agoSeeking Alpha

Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening

- In the first peer-reviewed, real-world, contemporary, comparative effectiveness study of TTR stabilizers in ATTR-CM using U.S. claims data, acoramidis was associated with a statistically and clinically significant 34% reduction in a composite of clinical worsening events (diuretic intensification, heart failure hospitalization, and mortality) versus tafamidis (p=0.046), supporting improved clinical stability of acoramidis over tafamidis - Acoramidis was also associated with a significant 43% r

7d agoYahoo Finance

Also Discussed

Investors talking about BBIO also mention

#	Name	Attention
1	Alnylam Pharmaceuticals, Inc.ALNY	0%0
2	Relay Therapeutics Inc.RLAY	0%new
3	IDEAYA Biosciences Inc.IDYA	0%-0.01
4	Ascendis Pharma A/SASND	0%new
5	Mineralys Therapeutics, Inc.MLYS	0%+0
6	SWTX - SpringWorks Therapeutics, Inc.	——
7	BPMC - Blueprint Medicines Corporation	——
8	Edgewise Therapeutics Inc.EWTX	0%new
9	Maze Therapeutics, Inc.MAZE	0%0
10	Madrigal Pharmaceuticals Inc.MDGL	0%-0.02

BridgeBio Pharma Inc.

Healthcare
Biotechnology

BridgeBio Pharma Inc. is a commercial-stage biopharmaceutical company focused on developing medicines for genetic conditions. BridgeBio Pharma Inc. discovers, develops, tests, and delivers therapies aimed at patients with rare and inherited diseases, with programs spanning cardiology, endocrinology, muscle disease, gene therapy, and selected oncology. The company’s current portfolio includes approved medicines such as Attruby for transthyretin amyloid cardiomyopathy and Nulibry for a rare metabolic disorder, alongside a pipeline of investigational treatments for additional genetic disorders. BridgeBio Pharma Inc. works with academic and industry partners to advance precision medicines and bring targeted treatment options to underserved patient groups. Headquartered in Palo Alto, California, BridgeBio Pharma Inc. plays a significant role in the genetic-disease biopharmaceutical market through its mix of commercial products and late-stage development programs.

Website

Location

3160 Porter Drive

Palo Alto, CA, 94304

United States

Social

What share of all stock conversation is about BBIO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.02	0.01% +0.01	0% 0	0% 0

Sep 23

BridgeBio Pharma's acoramidis has demonstrated real-world benefit versus tafamidis in ATTR-CM, reducing the risk of clinical worsening.
A new study evaluating the effectiveness of acoramidis versus tafamidis is expected to be released at an upcoming 2026 medical meeting.
Acoramidis is taking a healthy share of new starts with Attruby, with observational data favoring it by 34% on clinical worsening versus tafamidis.

Generated by AI

Sentiment

Of the messages about BBIO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	32.45% -45.81	59.36% -15.73	80.71% -2.24
Bearish	—	67.55% +45.81	40.64% +15.73	19.29% +2.24

Bullish· Apr 28

BridgeBio Pharma's ($BBIO) settlement with Pfizer ($PFE) has removed a significant overhang, providing clarity on the company's patent protection and improving its growth outlook.
Analysts are reiterating their bullish ratings on $BBIO, with price targets ranging from $100 to $157, citing improved IP visibility and limited near-term generic pressure.
The settlement with $PFE has led to a significant price increase for $BBIO, with the stock rising by 18% and reaching a new high, making it a "screaming buy" according to some investors.

Bearish· Apr 28

The market is disappointed with the PFE settlement, which extends exclusivity to 2031, a shorter timeframe than expected, and is a negative for $BBIO.
The recent price action forms a double top at around $85, a bearish technical signal, and some investors are choosing to exit positions.
The PFE lawsuit settlement likely delays cheap generic heart drugs to 2031, which is a positive for $BBIO's new drug outlook and stock sentiment.

Generated by AI

Topics

Of the messages about BBIO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	34.38%	69.05%	83.57%
Technical Analysis	—	6.25%	5.36%	3.12%
Macro	—	0%	0.6%	1.32%
Analysts	—	0%	2.38%	6.95%
Earnings	—	0%	0%	1.77%
Controversies	—	59.38%	22.62%	3.27%

Analysts· Jul 14

Jefferies initiated coverage of BridgeBio Pharma with a Buy rating and $70 price target.
Piper Sandler raised their price target on BridgeBio to $68 from $63, maintaining an 'Overweight' rating.
Leerink raised BridgeBio's price target to $56 from $53, and Scotiabank has a 'Sector Outperform' rating with a $55 price target.

Announcements· Apr 28

Pfizer has reached three settlement agreements for Vyndamax, which extends the patent expiry to June 1, 2031, giving BridgeBio Pharma more time to grow its rival heart drug.
BridgeBio Pharma is a primary competitor to Pfizer in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) market, and the company is on track for its worst day in 2.5 months due to the Pfizer connection.
BridgeBio Pharma has launched a health education effort on often overlooked heart condition featuring Attruby, and Barclays sees a 103% price potential after FDA approval of the drug Attruby.

Technical Analysis· Jul 18

The author is watching $BBIO for a potential short scalp if it starts rolling over, and notes that it looks exhausted.
$BBIO is massively overbought, with an RSI in the 90s, and the author expects a fall to begin soon.
The author is looking to add a short position on $BBIO at 33.50, with a target of 36.10, and notes that the stock is struggling to stay above $35 resistance.

Generated by AI

Community

Of the messages about BBIO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	98.85%	92.96%	79.32%
Newcomers	—	1.15%	7.04%	20.68%

Regulars· Sep 23

Acoramidis, BridgeBio Pharma's (BBIO) treatment for ATTR-CM, has demonstrated real-world benefit versus Tafamidis, reducing the risk of clinical worsening.
An upcoming 2026 medical meeting is expected to release additional, independent real-world study evaluating the effectiveness of Acoramidis versus Tafamidis using electronic health records data.
BBIO's valuation is considered cheap, with a potential market share forecast increase of 30-40%, possibly driven by an upcoming analyst day.

Newcomers· Feb 28

The FDA has approved Ascendis Pharma's (ASND) weekly treatment for children with dwarfism, a rare form of short stature, sparking an anticipated options flow and an increase in volume.
The approval of Yuviwel, a terapy for pediatric genetic dwarfism, is a significant event that may lead to a sector rotation, with related stocks such as BridgeBio Pharma (BBIO) potentially experiencing increased activity.
The FDA's approval of Yuviwel is a catalyst play that may attract investors, with options flow and volume expected to increase, and related stocks such as BridgeBio Pharma (BBIO) worth monitoring for sector movement.

Generated by AI

BridgeBio Pharma

Social

Sep 23

Bullish· Apr 28

Bearish· Apr 28

Analysts· Jul 14

Announcements· Apr 28

Technical Analysis· Jul 18

Regulars· Sep 23

Newcomers· Feb 28

The Bull Case For BridgeBio Pharma (BBIO) Could Change Following New ATTR Data Versus Tafamidis

BridgeBio Pharma (BBIO) Stock Looks Reasonable As Fresh Acoramidis Data Lands

BridgeBio Pharma Eyes Four Global Launches by 2027 as Attruby Nears Blockbuster Status

BridgeBio at bernstein healthcare forum: four-product growth story builds

BridgeBio says heart disease therapy Attruby beat Pfizer’s Vyndamax in real world study

Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening

Also Discussed

BridgeBio Pharma Inc.

Company Information

Location

The Bull Case For BridgeBio Pharma (BBIO) Could Change Following New ATTR Data Versus Tafamidis

BridgeBio Pharma (BBIO) Stock Looks Reasonable As Fresh Acoramidis Data Lands

BridgeBio Pharma Eyes Four Global Launches by 2027 as Attruby Nears Blockbuster Status

BridgeBio at bernstein healthcare forum: four-product growth story builds

BridgeBio says heart disease therapy Attruby beat Pfizer’s Vyndamax in real world study

Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening

Also Discussed

Social

Sep 23

Bullish· Apr 28

Bearish· Apr 28

Analysts· Jul 14

Announcements· Apr 28

Technical Analysis· Jul 18

Regulars· Sep 23

Newcomers· Feb 28